{"nctId":"NCT00798161","briefTitle":"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design","startDateStruct":{"date":"2008-12"},"conditions":["Diabetes Mellitus, Type 2"],"count":857,"armGroups":[{"label":"BI 1356 + metformin","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1356 + metformin"]},{"label":"matching placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: matching placebo"]},{"label":"BI 1356+ Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Bi 1356 + metformin"]},{"label":"Metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]},{"label":"metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: metformin"]},{"label":"BI 1356","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1356"]}],"interventions":[{"name":"BI 1356","otherNames":[]},{"name":"BI 1356 + metformin","otherNames":[]},{"name":"Bi 1356 + metformin","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"metformin","otherNames":[]},{"name":"matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nPatients with type 2 diabetes (drug naive or pre-treated) with insufficient glycaemic control (HbA1c higher or equal than 7.5 to less than 11.0 %), with very poor glycaemic control (HbA1c higher or equal than 11.0 %) who are not eligible for randomisation to be included in the open-label arm\n\nExclusion criteria:\n\nMyocardial infarction, stroke or transient ischemic attack (TIA), unstable or acute congestive heart failure, impaired hepatic function, treatment with rosiglitazone or pioglitazone, with a GLP1 analogue, with insulin, with anti-obesity drugs, with systemic steroids, renal failure or impairment, gastric bypass","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 24","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.11"},{"groupId":"OG001","value":"-0.64","spread":"0.08"},{"groupId":"OG002","value":"-1.07","spread":"0.08"},{"groupId":"OG003","value":"-0.45","spread":"0.08"},{"groupId":"OG004","value":"-1.22","spread":"0.08"},{"groupId":"OG005","value":"-1.59","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 6","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"},{"groupId":"OG001","value":"-0.45","spread":"0.05"},{"groupId":"OG002","value":"-0.61","spread":"0.05"},{"groupId":"OG003","value":"-0.36","spread":"0.06"},{"groupId":"OG004","value":"-0.86","spread":"0.05"},{"groupId":"OG005","value":"-1.00","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 12","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.11"},{"groupId":"OG001","value":"-0.61","spread":"0.07"},{"groupId":"OG002","value":"-0.95","spread":"0.07"},{"groupId":"OG003","value":"-0.42","spread":"0.07"},{"groupId":"OG004","value":"-1.13","spread":"0.07"},{"groupId":"OG005","value":"-1.37","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 18","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.12"},{"groupId":"OG001","value":"-0.66","spread":"0.08"},{"groupId":"OG002","value":"-1.06","spread":"0.08"},{"groupId":"OG003","value":"-0.45","spread":"0.08"},{"groupId":"OG004","value":"-1.17","spread":"0.08"},{"groupId":"OG005","value":"-1.54","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 24","description":"This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"5.3"},{"groupId":"OG001","value":"-15.8","spread":"3.5"},{"groupId":"OG002","value":"-32.2","spread":"3.6"},{"groupId":"OG003","value":"-8.6","spread":"3.6"},{"groupId":"OG004","value":"-33.2","spread":"3.5"},{"groupId":"OG005","value":"-49.4","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 2","description":"This change from baseline reflects the Week 2 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"4.3"},{"groupId":"OG001","value":"-19.6","spread":"2.9"},{"groupId":"OG002","value":"-21.8","spread":"2.9"},{"groupId":"OG003","value":"-13.0","spread":"2.9"},{"groupId":"OG004","value":"-34.5","spread":"2.9"},{"groupId":"OG005","value":"-38.6","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 6","description":"This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"4.7"},{"groupId":"OG001","value":"-20.8","spread":"3.2"},{"groupId":"OG002","value":"-31.6","spread":"3.2"},{"groupId":"OG003","value":"-10.8","spread":"3.2"},{"groupId":"OG004","value":"-38.7","spread":"3.2"},{"groupId":"OG005","value":"-48.3","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 12","description":"This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"5.0"},{"groupId":"OG001","value":"-21.8","spread":"3.3"},{"groupId":"OG002","value":"-31.9","spread":"3.4"},{"groupId":"OG003","value":"-8.4","spread":"3.4"},{"groupId":"OG004","value":"-36.2","spread":"3.4"},{"groupId":"OG005","value":"-49.9","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 18","description":"This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"5.1"},{"groupId":"OG001","value":"-13.7","spread":"3.4"},{"groupId":"OG002","value":"-30.3","spread":"3.5"},{"groupId":"OG003","value":"-9.2","spread":"3.4"},{"groupId":"OG004","value":"-34.6","spread":"3.4"},{"groupId":"OG005","value":"-48.1","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0% at Week 24","description":"The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"0"},{"groupId":"OG001","value":"18.6","spread":"0"},{"groupId":"OG002","value":"30.7","spread":"0"},{"groupId":"OG003","value":"10.4","spread":"0"},{"groupId":"OG004","value":"30.1","spread":"0"},{"groupId":"OG005","value":"53.6","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c<7.0 at Week 24","description":"The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"19.1","spread":null},{"groupId":"OG002","value":"31.2","spread":null},{"groupId":"OG003","value":"10.4","spread":null},{"groupId":"OG004","value":"30.7","spread":null},{"groupId":"OG005","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <6.5% at Week 24","description":"The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%. Only patients with baseline HbA1c =\\< 6.5%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0"},{"groupId":"OG001","value":"5.0","spread":"0"},{"groupId":"OG002","value":"12.3","spread":"0"},{"groupId":"OG003","value":"3.7","spread":"0"},{"groupId":"OG004","value":"13.1","spread":"0"},{"groupId":"OG005","value":"27.1","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c < 6.5% at Week 24","description":"The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"5.0","spread":null},{"groupId":"OG002","value":"12.3","spread":null},{"groupId":"OG003","value":"3.7","spread":null},{"groupId":"OG004","value":"13.1","spread":null},{"groupId":"OG005","value":"27.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c Lowering by 0.5% at Week 24","description":"The percentage of patients with an HbA1c reduction from baseline greater than 0.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":"0"},{"groupId":"OG001","value":"46.1","spread":"0"},{"groupId":"OG002","value":"65.9","spread":"0"},{"groupId":"OG003","value":"42.2","spread":"0"},{"groupId":"OG004","value":"71.5","spread":"0"},{"groupId":"OG005","value":"81.4","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Adjusted Means for 2h Post-Prandial Glucose (PPG) Change From Baseline at Week 24","description":"This change from baseline reflects the Week 24 2h PPG minus the baseline 2h PPG. Means are treatment adjusted for baseline HbA1c, baseline 2h PPG and previous anti-diabetic medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.4","spread":"23.2"},{"groupId":"OG001","value":"-82.9","spread":"14.4"},{"groupId":"OG002","value":"-87.2","spread":"14.8"},{"groupId":"OG003","value":"-35.3","spread":"16.1"},{"groupId":"OG004","value":"-86.0","spread":"17.5"},{"groupId":"OG005","value":"-109.2","spread":"16.2"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 24 for Open-label Patients","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percentage. Mean is unadjusted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.19","spread":"2.04"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 24 for Open-label Patients","description":"This change from baseline reflects the Week 24 FPG minus the baseline FPG. Mean is unadjusted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.58","spread":"70.94"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Therapy","description":"The use of rescue therapy (SUs, thiazolidinediones \\[TZDs\\], or insulin) was permitted only during the randomised treatment period of the trial (i.e. Visits 3 to 7), and was to be administered only if a patient had a 'confirmed' glucose level after an overnight fast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"13.5","spread":null},{"groupId":"OG002","value":"8.0","spread":null},{"groupId":"OG003","value":"11.1","spread":null},{"groupId":"OG004","value":"7.3","spread":null},{"groupId":"OG005","value":"4.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":72},"commonTop":["Hyperglycaemia","Diarrhoea","Nasopharyngitis","Hypertension","Glomerular filtration rate decreased"]}}}